文献速递临床试验与 GCP流行病学与生物统计

氨甲环酸预防贫血产妇产后出血:国际随机双盲安慰剂对照试验方案

Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2018-12-29

WOMAN-2试验为国际多中心随机双盲安慰剂对照研究,计划纳入1万名中重度贫血经阴道分娩产妇,产后15分钟内静脉注射1g氨甲环酸或安慰剂,主要结局为临床诊断原发性产后出血的比例;该试验旨在评估氨甲环酸预防贫血产妇产后出血的效果,预计提供可靠证据。

要点

  • 全球超三分之一孕妇贫血,贫血产妇产后出血风险及严重结局风险增加。
  • WOMAN-2试验计划纳入1万名中重度贫血阴道分娩产妇,随机接受1g氨甲环酸或安慰剂。
  • 主要结局为临床诊断原发性产后出血的比例,试验在非洲和亚洲医院开展。

核心结论

  • WOMAN-2试验旨在评估氨甲环酸对中重度贫血产妇产后出血的预防效果,预期为临床提供可靠证据。

研究设计与样本

  • 国际多中心随机双盲安慰剂对照试验,计划纳入1万名中重度贫血经阴道分娩产妇。
  • 干预为胎儿脐带结扎后15分钟内静脉注射1g氨甲环酸或匹配安慰剂。
  • 主要分析基于意向性治疗原则,结果以效应估计值及95%置信区间呈现。

主要发现

  • 原文未报告试验结果,仅描述研究方案。

关键数值与推荐

  • 主要结局为临床诊断原发性产后出血的产妇比例。
  • 样本量1万例时,检测产后出血率从10%相对降低25%至7.5%的把握度超过90%。
  • 亚组分析基于贫血严重程度(中度 vs 重度)和产程类型(引产或加强宫缩 vs 自然临产)。

临床怎么用

  • 若试验证实有效,可为贫血产妇产后出血预防提供氨甲环酸用药证据。

局限性

  • 原文为研究方案,尚无结果数据;试验仅纳入阴道分娩的中重度贫血产妇,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, most of which occur in low- and middle-income countries. Tranexamic acid (TXA) reduces bleeding by inhibiting the enzymatic breakdown of fibrin blood clots. TXA decreases blood loss in surgery and reduces death due to bleeding after trauma. When given within 3 h of birth, TXA reduces deaths due to bleeding in women with PPH. However, for many women, treatment of PPH is too late to prevent death. Over one third of pregnant women in the world are anaemic and many are severely anaemic. These women have an increased risk of PPH and suffer more severe outcomes if PPH occurs. There is an urgent need to identify a safe and effective way to reduce postpartum bleeding in anaemic women. METHODS/DESIGN: The WOMAN-2 trial is an international, multicentre, randomised, double-blind, placebo-controlled trial to quantify the effects of TXA on postpartum bleeding in women with moderate or severe anaemia. Ten thousand women with moderate or severe anaemia who have given birth vaginally will be randomised to receive 1 g of TXA or matching placebo by intravenous injection immediately (within 15 min) after the umbilical cord is cut or clamped. The primary outcome is the proportion of women with a clinical diagnosis of primary PPH. The cause of PPH will be described. Data on maternal health and wellbeing, maternal blood loss and its consequences, and other health outcomes will be collected as secondary outcomes. The main analyses will be on an 'intention-to-treat' basis, irrespective of whether the allocated treatment was received. Results will be presented as appropriate effect estimates with a measure of precision (95% confidence intervals). Subgroup analyses will be based on the severity of anaemia (moderate versus severe) and type of labour (induced or augmented versus spontaneous). A study with 10,000 patients will have over 90% power to detect a 25% relative reduction from 10 to 7.5% in PPH. The trial will be conducted in hospitals in Africa and Asia. DISCUSSION: The WOMAN-2 trial should provide reliable evidence for the effects of TXA for preventing postpartum bleeding in women with anaemia. TRIAL REGISTRATION: ISRCTN, ISRCTN62396133 . Registered on 7 December 2017; ClincalTrials.gov, ID: NCT03475342 . Registered on 23 March 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ker K, Roberts I, Chaudhri R, et al. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials. 2018. PMID: 30594227. doi:10.1186/s13063-018-3081-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。